Initiate KRYSTAL-10, a Phase 3 trial of adagrasib with cetuximab in 2nd line colorectal cancer
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- Q1 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Plan to initiate by Q2 2021 KRYSTAL-10 (849-010), a Phase 3 clinical trial of adagrasib in combination with cetuximab (ERBITUX®)2 in 2nd line colorectal cancer.”
What we found
Evidence strength A What the grades mean
The 10-Q filed 2021-08-05 and the 10-Q filed 2021-11-08 both state that the adagrasib plus cetuximab Phase 3 trial in 2nd line CRC was initiated in Q1 2021, before the Q2 2021 deadline.
-
A Mirati Therapeutics, Inc. 10-Q filed 2021-08-05
“In the first quarter of 2021, we initiated a Phase 3 clinical trial evaluating the combination of adagrasib and an anti-EGFR antibody (cetuximab) in patients in 2nd line CRC.” ✓ confirmed on the page
-
A Mirati Therapeutics, Inc. 10-Q filed 2021-11-08
“The second clinical trial is evaluating the combination of adagrasib and an anti-EGFR antibody (cetuximab) randomized against chemotherapy in patients with 2nd line CRC.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- KRYSTAL-10 Phase 3 trial of adagrasib with cetuximab
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Mirati Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C576263-024682 · Corrections policy